Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence and survival of hypopharyngeal cancer: a Danish Nation-Wide Study from 1980 to 2014

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dual-energy material decomposition for cone-beam computed tomography in image-guided radiotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Whole genome sequencing of breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: Following loco-regional treatment for early breast cancer accurate prognostication is essential for communicating benefits of systemic treatment. The aim of this study was to determine time to recurrence and long-term mortality rates in high risk patients according to patient characteristics and subtypes as assigned by immunohistochemistry panels.

PATIENTS AND METHODS: In November 1977 through January 1983, 2862 patients with tumors larger than 5 cm or positive axillary nodes were included in the DBCG 77 trials. Archival tumor tissue from patients randomly assigned to no systemic treatment was analyzed for ER, PR, Ki67, EGFR and HER2. Intrinsic subtypes were defined as follows: Luminal A, ER or PR >0%, HER2-negative, PR >10% and Ki67 < 14%; Luminal B, ER or PR >0%, (PR ≤10% or HER2-positive or Ki67 ≥ 14%); HER2E, ER 0%, PR 0%, HER2 positive; Core basal, ER 0%, PR 0%, HER2 negative and EGFR positive. Multivariate categorical and fractional polynomials (MFP) models were used to construct prognostic subsets by clinicopathologic characteristics.

RESULTS: In a multivariate model, mortality rate was significantly associated with age, tumor size, nodal status, invasion, histological type and grade, as well as subtype classification.

CONCLUSIONS: With 35 years of follow-up, in this population of high-risk patients with no systemic therapy, no subgroup based on a composite prognostic score and/or molecular subtypes could be identified without excess mortality as compared to the background population.

OriginalsprogEngelsk
TidsskriftActa oncologica (Stockholm, Sweden)
Vol/bind57
Udgave nummer1
Sider (fra-til)135-140
ISSN0284-186X
DOI
StatusUdgivet - 2018

ID: 52152674